Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience
复制标题
DOI：
10.1097/fjc.0000000000000893
复制
发表时间：
2020-10-01
影响因子：
3
通讯作者：
Di Micco, Pierpaolo
中科院分区：
文献类型：
--
作者：
Russo, Vincenzo;Cardillo, Giuseppe;Di Micco, Pierpaolo
肝素的使用已被证明可以降低重症 COVID-19 住院患者的死亡率。我们的研究目的是评估磺达肝素与依诺肝素在 100 名住院的 COVID-19 患者中预防静脉血栓栓塞的临床影响。比较了接受磺达肝素治疗的患者与接受依诺肝素治疗的患者之间的肺栓塞、深静脉血栓形成、大出血 (MB)、临床相关的非 MB、急性呼吸窘迫综合征和院内死亡率。两组的人口统计学、实验室和临床特征均相同。在中位随访 28 天（IQR：12-45）天中，静脉血栓栓塞（14.5% vs. 5.3%；P = 0.20）、MB 和临床相关非 MB（3.2% vs. 5.3%，P = 0.76）、ARDS（17.7% vs. 15.8%；P = 0.83）和依诺肝素组与磺达肝素组之间显示出院内死亡率（9.7% vs. 10.5%；P = 0.97）。我们的初步结果支持在内科住院的 COVID-19 患者中安全有效地使用磺达肝素的假设。
The use of heparin has been shown to decrease the mortality in hospitalized patients with severe COVID-19. The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients. The incidence of pulmonary embolism, deep venous thrombosis, major bleeding (MB), clinically relevant non-MB, acute respiratory distress syndrome, and in-hospital mortality was compared between patients on fondaparinux versus enoxaparin therapy. The 2 groups were homogeneous for demographic, laboratory, and clinical characteristics. In a median follow-up of 28 (IQR: 12-45) days, no statistically significant difference in venous thromboembolism (14.5% vs. 5.3%; P = 0.20), MB and clinically relevant non-MB (3.2% vs. 5.3%, P = 0.76), ARDS (17.7% vs. 15.8%; P = 0.83), and in-hospital mortality (9.7% vs. 10.5%; P = 0.97) has been shown between the enoxaparin group versus the fondaparinux group. Our preliminary results support the hypothesis of a safe and effective use of fondaparinux among patients with COVID-19 hospitalized in internal medicine units.